Monotherapy for postmenopausal women w/ estrogen receptor +ve & HER2 -ve if not previously treated w/ endocrine therapy, locally advanced or metastatic breast cancer w/ disease relapse on or after adjuvant endocrine therapy or disease progression on endocrine therapy. In combination w/ ribociclib for postmenopausal women w/ hormone-receptor (HR) +ve, HER2 -ve advanced or metastatic breast cancer as initial therapy or following disease progression. In combination w/ palbociclib for women who have received prior endocrine therapy w/ HR +ve, HER2 -ve locally advanced or metastatic breast cancer.
Adult female including elderly 500 mg at 1 mth interval w/ additional 500-mg dose given 2 wk after initial dose, administered 1 in each buttock as 2 consecutive 5 mL slow IM inj.
Bleeding diatheses, thrombocytopenia; thromboembolic events; potential risk of osteoporosis; critical visceral disease. Dorsogluteal inj site due to proximity of underlying sciatic nerve. Interfered Ab-based estradiol assays. Concomitant use w/ anticoagulants. May affect ability to drive & use machines. Mild to moderate hepatic impairment. Severe renal impairment (CrCl <30 mL/min). Women of childbearing potential should use effective contraception. Not to be used during pregnancy & lactation. Not recommended in childn & adolescents.
Manage Account
Change Password
Sign Out
 250 mg_5 mLd2791556-3e02-4b42-b91b-9faa000a41fc.GIF)
